NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

$66.61

-0.61 (-0.91 %)

(As of 06/18/2021 12:00 AM ET)

Add

Compare

Today's Range

$65.89

▼

$67.18

50-Day Range

$63.47

▼

$69.35

52-Week Range

$56.56

▼

$78.94

Volume11.46 million shs

Average Volume8.05 million shs

Market Capitalization$83.54 billion

P/E Ratio289.62

Dividend Yield4.22%

Beta0.38

30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

About Gilead Sciences

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
June 18, 2021 | nasdaq.com

Is Gilead a Great Value Stock Right Now?
June 18, 2021 | stocknews.com

Kite, Shoreline Biosciences In Strategic Partnership To Develop Novel Allogeneic Cell Therapies
June 17, 2021 | markets.businessinsider.com

Gilead's Kite Pharma Collaborates With Shoreline Biosciences For Cell Therapies For Cancer Settings
June 17, 2021 | benzinga.com

Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
June 17, 2021 | finance.yahoo.com

Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement with Gilead Sciences and FDA Clearance of Investigational New Drug Application for Anti-CCR8 Antibody
June 15, 2021 | finance.yahoo.com

Is it time for Americans to drop their infatuation with the PCR test? That’s what this COVID-19 testing expert thinks
June 14, 2021 | msn.com

$Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis$

Longer-term Data for Kite’s Yescarta® in Relapsed or Refractory Follicular Lymphoma Demonstrate Substantial Survival Improvement Over Current Therapies in Comparative Analysis
June 12, 2021 | finance.yahoo.com

Twist Bioscience (NASDAQ:TWST) vs. Gilead Sciences (NASDAQ:GILD) Head-To-Head Comparison
June 12, 2021 | americanbankingnews.com

Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
June 11, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
Previous Symbol
CUSIP37555810
CIK882095
Webwww.gilead.com
Phone(650) 574-3000
Employees13,600
Year Founded1987

Sales & Book Value

Annual Sales$24.69 billion
Price / Sales3.38
Cash Flow$8.06 per share
Price / Cash Flow8.26
Book Value$14.54 per share
Price / Book4.58

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares1,254,178,000
Market Cap$83.54 billion
Next Earnings Date7/29/2021 (Estimated)
OptionableOptionable

Social Links

MarketRank^™

Overall MarketRank^™

2.77 out of 5 stars

Medical Sector

2nd out of 2,097 stocks

Biological Products, Except Diagnostic Industry

1st out of 198 stocks

4.3 Analyst's Opinion

Consensus Rating
Gilead Sciences has received a consensus rating of Buy. The company's average rating score is 2.55, and is based on 11 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $100.59, Gilead Sciences has a forecasted upside of 51.0% from its current price of $66.61.
Amount of Analyst Coverage
Gilead Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.3 Community Rank

Outperform Votes
Gilead Sciences has received 2,395 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Gilead Sciences has received 1,253 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Gilead Sciences has received 65.65% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote “Outperform” if you believe GILD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Gilead Sciences is a leading dividend payer. It pays a dividend yield of 4.22%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Gilead Sciences has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Gilead Sciences is 40.06%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 41.46% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,309,609.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Gilead Sciences is held by insiders.
Percentage Held by Institutions
77.18% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Gilead Sciences are expected to decrease by -3.11% in the coming year, from $7.07 to $6.85 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gilead Sciences is 289.62, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 30.05.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gilead Sciences is 289.62, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 43.96.
Price to Earnings Growth Ratio
Gilead Sciences has a PEG Ratio of 0.63. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Gilead Sciences has a P/B Ratio of 4.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

Is Gilead Sciences a buy right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 9 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Gilead Sciences stock.
View analyst ratings for Gilead Sciences or view top-rated stocks.

What stocks does MarketBeat like better than Gilead Sciences?

Wall Street analysts have given Gilead Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Gilead Sciences.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings results on Thursday, April, 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, topping the Zacks' consensus estimate of $2.06 by $0.02. The biopharmaceutical company earned $6.42 billion during the quarter, compared to analyst estimates of $6.78 billion. Gilead Sciences had a trailing twelve-month return on equity of 51.91% and a net margin of 1.18%.
View Gilead Sciences' earnings history.

How has Gilead Sciences' stock price been impacted by Coronavirus (COVID-19)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GILD stock has decreased by 9.6% and is now trading at $66.61.
View which stocks have been most impacted by COVID-19.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, April 29th. Investors of record on Tuesday, June 15th will be given a dividend of $0.71 per share on Tuesday, June 29th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.26%. The ex-dividend date is Monday, June 14th.
View Gilead Sciences' dividend history.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.84 per share and currently has a dividend yield of 4.22%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences does not yet have a strong track record of dividend growth. The dividend payout ratio of Gilead Sciences is 40.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 41.46% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences updated its FY 2021 earnings guidance on Thursday, May, 6th. The company provided earnings per share guidance of 6.750-7.450 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.170. The company issued revenue guidance of $21.70 billion-$22.10 billion, compared to the consensus revenue estimate of $24.78 billion.

What price target have analysts set for GILD?

20 equities research analysts have issued twelve-month target prices for Gilead Sciences' shares. Their forecasts range from $61.00 to $625.00. On average, they anticipate Gilead Sciences' share price to reach $100.59 in the next twelve months. This suggests a possible upside of 51.0% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:

Mr. Daniel P. O'Day, Chairman & CEO (Age 57, Pay $7.48M)
Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 51, Pay $2.71M)
Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53, Pay $2.71M)
Ms. Johanna Mercier, Chief Commercial Officer (Age 51, Pay $4.86M)
Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 58, Pay $3.85M)
Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 59)
Ms. Jacquie Ross C.F.A., VP of Investor Relations
Ms. Jyoti K. Mehra, Exec. VP of HR
Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 67)
Dr. Diana M. Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 50)

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of GILD's competitors.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.91%), Capital International Investors (3.19%), Geode Capital Management LLC (1.65%), Northern Trust Corp (1.21%), Bank of New York Mellon Corp (1.04%) and Morgan Stanley (0.74%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Franklin Resources Inc., Cibc World Markets Corp, Camber Capital Management LP, Neuberger Berman Group LLC, DnB Asset Management AS, Price T Rowe Associates Inc. MD, and AQR Capital Management LLC. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Javier Rodriguez, Merdad Parsey, and Richard James Whitley.
View insider buying and selling activity for Gilead Sciences or view top insider-selling stocks.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Sarissa Capital Management LP, Amundi Asset Management US Inc., Morgan Stanley, Parnassus Investments CA, Factorial Partners LLC, and Woodline Partners LP.
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $66.61.

How much money does Gilead Sciences make?

Gilead Sciences has a market capitalization of $83.54 billion and generates $24.69 billion in revenue each year. The biopharmaceutical company earns $123 million in net income (profit) each year or $7.09 on an earnings per share basis.

How many employees does Gilead Sciences have?

Gilead Sciences employs 13,600 workers across the globe.

Does Gilead Sciences have any subsidiaries?

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences llac Ticaret Limited Sirketi, Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, Kite Pharma UK Ltd, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

Where are Gilead Sciences' headquarters?

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 574-3000 or via email at [email protected]

This page was last updated on 6/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here